Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of ...
Nov 29, 2011
0
0